Paving a Pathway to Pharma 4.0

February 21, 2020|BiopharmaTrend | By Cathal Strain

Life sciences manufacturers must embrace digital transformation whether they are making small or large molecule drugs, or cell or gene therapies. In this piece for BiopharmaTrend, Neo President Cathal Strain lays out a pathway to digitization to improve manufacturing reliability, reduce costs and—most importantly—ensure patients receive the highest-quality drug therapies.